Clinical

Medical experts discuss the long-term consequences of extended use of topical corticosteroids or calcineurin inhibitors in atopic dermatitis (AD) patients and recommend appropriate monitoring strategies.

The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management.

Quality of life was also a top concern among patients when asked about their priorities if they experienced relapse or were refractory to therapy.

Patients with rheumatoid arthritis and obesity exhibited worse scores for subjective measures like pain and fatigue compared with those without obesity.

An adeno-associated virus (AAV) gene therapy for hereditary spastic paraplegia type 50 (SPG50)—funded by a young patient’s family—gives hope not only to a 4-year-old, but to researchers working on similar projects for other rare diseases.

Based on the 2024 State of the Air report, Munaf Siyamwala, MD, of Centerpoint Medical Center, noted that patients with COPD need personalized action plans to manage flare-ups exacerbated by poor air quality and extreme weather conditions.

The 5 agents in ViPOR—including venetoclax and lenalidomide—worked better together in a phase 1b/2 trial than they previously have, individually, in treating patients with certain diffuse large B-cell lymphoma (DLBCL) subtypes.

Researchers found no significant differences in disease-free survival, overall survival, and recurrence rates between fertility-sparing surgery and radical surgery for patients with stage I epithelial ovarian cancer.

Patients with atopic dermatitis, particularly males and those aged 40 to 59 years, have significantly higher rates of impaired mobility.

Munaf Siyamwala, MD, of Centerpoint Medical Center, explained that summertime heatwaves and increased pollution significantly exacerbate symptoms for patients with chronic obstructive pulmonary disease (COPD).

Israeli patients with vitiligo exhibit a significantly reduced risk of developing Parkinson disease (PD).

Only about 1% of patients with chronic lymphocytic leukemia (CLL) developed an invasive fungal infection while on a Bruton’s tyrosine kinase (BTK) inhibitor, investigators found.

High neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR) are associated with worse progression-free survival and 5-year overall survival in patients with ovarian cancer.

The field of sarcoma study is getting more specific, with clinical investigations drilling down to more specific subtypes of soft tissue sarcoma for better targeted therapies.

In April, the FDA approved decabtagene vicleucel (ide-cel) for earlier treatment of relapsed/refractory multiple myleoma.

Of 7 subtypes identified 10,000 melanoma cells, C4 Melanoma COCO1A was the only to show indications of being more sensitive to natural killer (NK) and T cells.

Leda Mannent, MD, global project head, Immunology and Inflammation, Sanofi, discusses efficacy outcomes in patients with asthma who received rilzabrutinib.

Experts on chronic spontaneous urticaria outline the hallmark symptoms most associated with the disease and how they fluctuate with time.

A panel of experts describe the pathophysiology of chronic spontaneous urticaria.

Different types of assays led to different results in measures of factor IX variant FIX-R338L, the authors found.

Patients who used adjuvant chemotherapy were found to have a higher survival rate after achieving complete pathological response.

An oncologist specializing in breast cancer treatment reviews the latest guideline recommendations for systemic therapies in HR+/HER2- breast cancer, comparing the available CDK4/6 inhibitors and discussing considerations for optimal treatment sequencing.

William J. Gradishar, MD, provides an overview of the current breast cancer treatment landscape, highlights updates to the NCCN guidelines from 2023 to 2024, and expresses optimism for addressing unmet needs at ASCO 2024.

Today, the FDA approved ensifentrine (Ohtuvayre; Verona Pharma) for the maintenance treatment of moderate to severe chronic obstructive pulmonary disease (COPD) based on the successful phase 3 ENHANCE trials.

The CDC issued a warning to doctors on Tuesday to look out for dengue cases amid a global surge; HHS has finalized disincentives to prevent health care organizations from unreasonably blocking the exchange of electronic health record (EHR) information; patients in some states, like West Virginia, cannot afford weight-loss medications due to the high costs and lack of insurance coverage.